Abstracts tagged "fibromyalgia"

Abstract Number: 1083 • 2013 ACR/ARHP Annual Meeting
Something Ventured, Something Gained: Alternative Therapies For FMS and RA
Robert S. Katz¹, Hannah Bond², Jessica L. Polyak², Lauren Kwan², Alexandra Small³ and Susan Shott⁴, ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL, ³University of Illinois Medical School, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Many patients with rheumatologic diseases resort to unproven alternative therapies. We compared FMS and RA patients with respect to the use and effectiveness…
Abstract Number: 133 • 2013 ACR/ARHP Annual Meeting
Cross-Sectional Neurocognitive Data Do Not Support a Transition From Fibrofog To Alzheimer’s Disease In Fibromyalgia Patients
Robert S. Katz¹ and Frank Leavitt², ¹Rush Medical College, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: The issue of progressive decline in cognitive abilities is a source of concern to many patients with fibromyalgia. The fear of progressing from fibrofog…
Abstract Number: 1084 • 2013 ACR/ARHP Annual Meeting
Age Distribution of Women With Idiopathic and Traumatic Fibromyalgia
Robert S. Katz¹ and Frank Leavitt², ¹Rush Medical College, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia has both idiopathic and post traumatic forms. The idiopathic type is insidious in onset, becoming established without a known triggering event. The post-traumatic…
Abstract Number: 134 • 2013 ACR/ARHP Annual Meeting
Lower Socioeconomic Status Associates With Increased Symptom Severity and Functional Impairment In Fibromyalgia
Mary-Ann Fitzcharles¹, Emmanouil Rampakakis^2,3, Peter A. Ste-Marie⁴, John S. Sampalis^2,3 and Yoram Shir⁴, ¹Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Persons with lower socioeconomic status (SES) have poorer health status for many medical conditions. Reasons for this finding are multiple, but access to care,…
Abstract Number: 839 • 2013 ACR/ARHP Annual Meeting
A Paradigm Change for Treatment Strategies for Fibromyalgia Syndrome Reflected By Recommendations of Recent Evidence-Based Interdisciplinary Guidelines Developed Independently in Three Countries
Jacob N. Ablin¹, Dan Buskila², Howard Amital³, Mary-Ann Fitzcharles⁴, Yoram Shir⁵, Peter Henningsen⁶ and Winfried Häuser⁷, ¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Ben-Gurion University, Beer-Sheva, Israel, ³Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ⁴Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁵Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁶Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, Germany, ⁷Klinikum Saarbrücken, Saarbrücken, Germany
Background/Purpose: Although the ideal treatment for fibromyalgia (FM) remains elusive, the medical community requires direction in the care of these patients. The literature however abounds…
Abstract Number: 136 • 2013 ACR/ARHP Annual Meeting
The Detection Of Primary Hyperparathyroidism In Patients Diagnosed With Fibromyalgia
Michael Tsoukas¹, Peter A. Ste-Marie², Yoram Shir², Mary-Ann Fitzcharles³ and Elliot Mitmaker⁴, ¹Endocrinology, McGill University Health Centre, Montreal, QC, Canada, ²Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴General and Endocrine Surgery, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Some illnesses, such as hypothyroidism or small fiber neuropathy, may present similarly to fibromyalgia (FM), or may in turn lead to an augmented polysymptomatic…
Abstract Number: 841 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Fibromyalgia In The General Population – a Comparison Of The ACR 1990, 2010 and Modified 2010 Classification Criteria
Gareth T. Jones¹, Marcus Beasley¹, Fabiola Atzeni², Elisa Flüß¹, Piercarlo Sarzi-Puttini² and Gary Macfarlane¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: In 1990 the ACR published criteria for the classification of fibromyalgia (FM), based on widespread pain and tenderness. In 2010 new criteria were published…
Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Daniel J. Wallace¹, Igor Gavin², Oleksiy Karpenko² and Bruce S. Gillis³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Illinois College of Medicine at Chicago, Chicago, IL, ³Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…
Abstract Number: 2849 • 2013 ACR/ARHP Annual Meeting
Medication Adherence and Healthcare Costs Among Patients With Fibromyalgia: Combination Medication Versus Duloxetine, Pregabalin, and Milnacipran Initiators
Nicole Marlow¹, Kit Simpson², James Zoller² and E. Baron Short³, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Healthcare Leadership and Management, Medical University of South Carolina, Charleston, SC, ³Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
Background/Purpose: The combined use of prescription drugs (Rx) with complementary mechanisms of action has been described for treating fibromyalgia (FM). We examined medication adherence and…
Abstract Number: 2850 • 2013 ACR/ARHP Annual Meeting
Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Lesley M. Arnold¹, Pierre Arsenault², Cynthia Huffman³, Jeffrey L. Patrick⁴, Michael Messig⁴, Marci L. Chew⁴, Luis Sanin⁴, Lynne Pauer⁴ and Andrew Clair⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Meridien Research, Tampa, FL, ⁴Pfizer Inc, New York, NY
Background/Purpose: Pregabalin (PGB) is currently approved for the treatment of fibromyalgia (FM) for twice daily dosing over a range of 300-450 mg/day. A pregabalin controlled-release…
Abstract Number: 2852 • 2013 ACR/ARHP Annual Meeting
Real-Life Assessment Of The Validity Of Patient Global Impression Of Change In Fibromyalgia
John S. Sampalis^1,2, Mary-Ann Fitzcharles³, Peter A. Ste-Marie⁴, Emmanouil Rampakakis^1,2 and Yoram Shir⁴, ¹JSS Medical Research, Montreal, QC, Canada, ²Jewish General Hospital, McGill University, Montreal, QC, Canada, ³Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Assessing fibromyalgia (FM) is challenging due to the lack of hard outcomes and the need to rely on patient-reported symptoms. Completion of questionnaires by…
Abstract Number: 2092 • 2013 ACR/ARHP Annual Meeting
Strengthening Exercises Using A Swiss Ball Improve Symptoms and Muscle Performance Of Patients With Fibromyalgia: A Randomized Controlled Study
Josiander Arakaki Sr., RHEUMATOLOGY, UNIFESP, sao paulo, Brazil
Background/Purpose: Fibromyalgia (FM) is a disorder characterized by chronic widespread pain, fatigue and reduced muscle strength. Exercise is fundamental to the treatment of FM and…
Abstract Number: 1948 • 2013 ACR/ARHP Annual Meeting
Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia
Rafael Chakr¹, Marina Behar², José A. Mendonça³, Daniela Cervantes², Nizele Calegaro², Nicole Andrade², Iuri Siqueira², Daniel Zanchet², Andrese Gasparin², Penélope Esther Palominos², Charles Kohem⁴, Odirlei Andre Monticielo⁵, Claiton Brenol⁶, Ricardo M. Xavier² and João Carlos T. Brenol⁷, ¹Rheumatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ³Rheumatology, Pontifical Catholic University of Campinas / Institute of Clinical Research – IPECC, Campinas, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ⁵Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ⁷Rheumatology Division, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: Fibromyalgia (FM) falsely increases rheumatoid arthritis (RA) disease activity clinical composite scores, such as the simplified disease activity index (SDAI), recently incorporated into ACR/EULAR…
Abstract Number: 140 • 2013 ACR/ARHP Annual Meeting
Fibromyalgia and Pregnancy: Challenges Of The Savella^® (Milnacipran) Pregnancy Registry
Damien Hirsch¹, Denise Leclair¹, Robert H. Palmer¹, Vikki Brown², Susan Sinclair Roberts^2,3 and Janice McLean², ¹Forest Research Institute, Inc., Jersey City, NJ, ²INC Research, LLC, Wilmington, NC, ³University of North Carolina Wilmington, Wilmington, NC
Background/Purpose: During pregnancy, women with fibromyalgia (FM) often experience worsening of symptoms, which include widespread pain, fatigue, sleep disturbances, cognitive difficulties, and reduced daily functioning.…
Abstract Number: 1101 • 2013 ACR/ARHP Annual Meeting
Neuromuscular Taping On Patients With Fibromyalgia May Be a Useful Tool To Relief Muscular Pain
Camillo Giacomelli, Antonino Santagati, Arianna Consensi, Alessandra Rossi, Stefano Bombardieri and Laura Bazzichi, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Fibromyalgia (FMS) is an illness characterized by an anomalous perception of the painful stimuli that are supposed to be attributable to a combination of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].